Diabetes Around the World

Diabetes Around the World

Diabetes Around the World: Who Is Affected, How Serious It Is, and How It’s Managed

The global picture (2025)

  • 589 million adults (20–79) are living with diabetes—1 in 9 people worldwide. IDF projects 853 million by 2050. Direct health spending is ~US$1 trillion annually. In 2024, diabetes was linked to ~3.4 million deaths (about one every 9 seconds). (Diabetes Atlas, International Diabetes Federation)
  • WHO estimates 1.6 million deaths were directly due to diabetes in 2021, with nearly half before age 70; diabetes also drives kidney disease and a sizable share of cardiovascular deaths. (World Health Organization)

Where diabetes is most common

IDF’s latest regional estimates (adults 20–79) show the heaviest absolute burden in Asia–Pacific, with rapid growth in every region:

  • Western Pacific: ~215 million
  • South-East Asia: ~107 million
  • Middle East & North Africa: ~85 million
  • Europe: ~66 million
  • North America & Caribbean: ~56 million
  • South & Central America: ~35 million
  • Africa: ~25 million (fastest relative growth projected) (Diabetes Atlas)

At the country level, several Pacific Island nations have some of the world’s highest age-standardized prevalence rates; for example, Nauru ~20% of adults. (Diabetes Atlas)

Ethnicity & place: who’s at higher risk?

Diabetes risk is not evenly distributed across populations—even at similar body weights.

  • South Asian, Southeast Asian, Black and many minority groups in high-income countries have 2–6× higher type 2 diabetes (T2D) risk than White host populations, often at younger ages and lower BMI. (PMC, PubMed)
  • Large meta-analyses support lower BMI action thresholds for some groups (e.g., Asian BMI ≥23 as “overweight” for cardiometabolic risk) and provide ethnicity-specific cut-offs tied to diabetes risk. (PMC)
  • Indigenous peoples in several regions exhibit extremely high rates when exposed to rapid lifestyle change. The Pima (Akimel O’odham) in Arizona historically recorded some of the highest T2D prevalence; comparative studies show much lower rates among related groups maintaining traditional diets and higher physical activity, underscoring the environment–genetics interaction. (Diabetes Journals, PMC)
  • Pacific Islanders (e.g., American Samoa, Fiji) show some of the highest incidence globally, paralleling shifts toward urbanized diets and lower activity. (PMC)

Why it’s serious

  • Beyond deaths, diabetes drives disability-adjusted life years (DALYs) worldwide and is rising with population aging and urbanization. (The Lancet)
  • Major complications include heart disease, stroke, kidney failure, blindness, neuropathy, foot ulcers and amputations; a large share of cases are undiagnosed—IDF estimates ~252 million adults don’t know they have diabetes. (World Health Organization, International Diabetes Federation)

How diabetes is detected

  • Who should be screened?
    • ADA (2025): screen all adults starting at age 35, and earlier if overweight/obese with risk factors (e.g., high-risk ethnicity, family history). Test every 3 years if normal; yearly if prediabetes. (Wisconsin Academy of Family Physicians)
    • USPSTF (U.S., 2021): screen ages 35–70 with overweight/obesity; consider earlier/lower BMI thresholds in Asian or other higher-risk groups. (USPSTF)
  • How is it diagnosed?
    • Fasting plasma glucose, A1C, or 75-g oral glucose tolerance test, using standard ADA/WHO cut-points. (Diabetes Journals)

How diabetes is managed worldwide (what most guidelines agree on)

1) Foundations of care for everyone with diabetes

2) Glycemic targets

  • For most non-pregnant adults, A1C <7% (53 mmol/mol) balances benefits and hypoglycemia risk; targets are individualized (e.g., stricter in younger/healthier, looser in frail/multimorbid). (www.heart.org)

3) Glucose-lowering medications (Type 2 diabetes)

  • Metformin is a common first-line agent where not contraindicated, given its efficacy, safety, and cost. (PMC)
  • For people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure, start or add agents with proven cardiorenal benefit:
    • SGLT2 inhibitors (renal/HF protection, CV benefit)
    • GLP-1 receptor agonists (CV benefit and weight loss)
      These choices may be prioritized regardless of baseline A1C or metformin use per ADA 2024–2025 updates and IDF 2025 recommendations. (Diabetes Journals, International Diabetes Federation)
  • Other classes (DPP-4 inhibitors, thiazolidinediones, insulin, sulfonylureas) are used based on A1C gap, comorbidities, hypoglycemia risk, cost, and access. Insulin is essential for type 1 and for type 2 when oral/GLP-1/SGLT2 therapies aren’t enough. (Diabetes Journals)

4) Blood pressure and lipids (risk-factor control saves lives)

  • Treat hypertension to <130/80 mmHg for most adults with diabetes; use ACEi/ARB-based regimens, often as single-pill combinations to improve adherence (WHO/ADA/ESH). (Diabetes Journals, World Health Organization)
  • Use statins (and add-ons as needed) for LDL reduction per risk level; aggressive risk-factor control substantially cuts CV events. (ADA Standards, IDF.) (Diabetes Professionals)

5) Complication screening

  • Annual: kidney disease (UACR/eGFR), eye disease (retinal exam), neuropathy/foot checks; routine vaccines; and time-in-range/A1C monitoring at intervals guided by therapy. (ADA/IDF.) (Diabetes Professionals)

6) Equity and culture matter

  • Because risk and outcomes vary by ethnicity, migration history, and socioeconomic context, guidelines encourage culturally adapted education, use of interpreters/materials in local languages, and lower diagnostic/BMI thresholds where appropriate (e.g., Asian BMI). These steps improve adherence and outcomes. (PMC)

What this means for different places

  • Asia–Pacific carries the largest absolute burden—especially China, India, and Western Pacific nations—with high prevalence in Pacific Islands. Rapid urbanization and dietary shifts drive the trend. (Diabetes Atlas, PMC)
  • Middle East & North Africa has very high age-specific prevalence tied to obesity and inactivity, with major health-system costs. (Diabetes Atlas)
  • Sub-Saharan Africa still shows the lowest absolute counts but the fastest growth and high undiagnosed proportions, straining resources. (Diabetes Atlas)
  • Europe & North America face large burdens among minority and migrant communities and older adults; many cases remain untreated or above targets. (PMC, World Health Organization)

Key takeaways for the public

  1. Diabetes already affects 1 in 9 adults globally and is still rising. Early detection (screening by age 35 or earlier if high risk) prevents complications. (International Diabetes Federation, Wisconsin Academy of Family Physicians)
  2. Risk is shaped by where you live and your background; some groups need earlier screening and lower BMI thresholds. (USPSTF, PMC)
  3. The most effective care combines lifestyle support, evidence-based medications (often SGLT2/GLP-1 for heart/kidney protection), and tight control of blood pressure and lipids. (Diabetes Journals)
  4. Culturally tailored education and access to affordable medicines/technology are essential to close ethnic and regional gaps. (PMC)

Sources (high-level)

 

Author